Dr. Melamede Confirms Pre-IND Procedures Are in Motion for Pre-IND Meeting With the FDA and Plans Corporate Headquarters Move to Colorado Springs, Colorado

SAN FRANCISCO, CA -- (MARKET WIRE) -- Cannabis Science Inc. (OTCBB: CBIS), an emerging cannabis pharmaceutical company, is pleased to announce that the Company is moving forward with its preparations for a pre-IND meeting with the FDA, which will provide guidance on the manufacturing, non-clinical, and clinical development program for Cannabis Science Drugs. As well the Company reports intentions to move corporate headquarters to Colorado Springs, Colorado. Dr. Melamede is currently in discussion with facilities in the Colorado Springs area.

"It is very important to understand that our initial drug formulation is ready now, which often costs major pharmaceutical companies millions of dollars to reach this stage. Our initial pre-IND work will establish non-clinical product safety (safety pharmacology, pharmacokinetics, and toxicology) under FDA guidelines. We are also identifying and establishing appropriate GMP compliant testing and manufacturing facilities. If the assumptions we make about pre-existing information are accurate, our costs in time and money to get to the pre-IND meeting with the FDA will be much less because our initial drug formulation is ready now. We look forward to working with the FDA and to following their recommendations with the steps that are required to ultimately produce our first FDA approved pharmaceutical product," stated, Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. It is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.